Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments have been revised. It is anticipated that the appraisal will begin in mid-June 2023 when we will write to you about how you can get involved.